Mucociliary Clearance Clinical Trial
Official title:
An Open-Label, 2-way Crossover Placebo-Controlled , Radio-Labeled Tracer Study Evaluating the Effect of MUCINEX® 1200 mg on Mucociliary and Cough Clearance From The Human Lung In Healthy, Non-Smoking Adults
The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00951522 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT00999531 -
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00325767 -
Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol
|
Phase 4 | |
| Completed |
NCT05875025 -
Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance
|
Phase 1 | |
| Recruiting |
NCT05755932 -
Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants
|
Phase 3 | |
| Withdrawn |
NCT01025713 -
A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)
|
Phase 1 |